Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Feb;21(1):93-103.
doi: 10.1023/a:1027347010332.

The effect of sodium aurothiomalate on stimulated and non-stimulated migration by human neutrophils: the role of cyclic GMP

Affiliations

The effect of sodium aurothiomalate on stimulated and non-stimulated migration by human neutrophils: the role of cyclic GMP

J G Elferink et al. Inflammation. 1997 Feb.

Abstract

Preincubation of human neutrophils with aurothiomalate had little effect on random migration or chemotactic migration towards the chemotactic peptide fMLP. However, a strong enhancement of migration was observed when aurothiomalate was present in a concentration gradient; the effect of the drug was chemotactic rather than chemokinetic. Thiomalate also caused a chemotactic enhancement of migration but here a tenfold higher concentration of the drug was required as compared with aurothiomalate. Aurothiomalate caused an increase of cellular cGMP level, and inhibitors of guanylate cyclase inhibited the activating effect of aurothiomalate. Three specific antagonists of cGMP-dependent kinase (G-kinase) strongly inhibited aurothiomalate-induced migration of electroporated neutrophils. The results suggest that stimulation of migration by aurothiomalate is mediated by cGMP and a G-kinase. Monoclonal anti-IL-8 inhibited aurothiomalate-induced stimulation of migration. Though no increased release of IL-8 could be established upon exposure of neutrophils to aurothiomalate, it seems conceivable that the stimulating effect of aurothiomalate is mediated by IL-8.

PubMed Disclaimer

Similar articles

References

    1. Arthritis Rheum. 1983 Jan;26(1):82-6 - PubMed
    1. Rheumatol Int. 1992;12(4):159-64 - PubMed
    1. J Pharmacol Exp Ther. 1981 Oct;219(1):181-6 - PubMed
    1. Biochem Pharmacol. 1989 Oct 1;38(19):3383-6 - PubMed
    1. J Pharmacol Exp Ther. 1988 Oct;247(1):283-8 - PubMed

MeSH terms

LinkOut - more resources